Jump to ContentJump to Main Navigation

Online

99,00 € / $149.00*

* Prices subject to change. Shipping costs will be added if applicable.
ISSN:
2191-0162

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 99.00
RRP for USA, Canada, Mexico
US$ 149.00 *
Print
Individual Subscription Online only
Euro [D] 383.00
RRP for USA, Canada, Mexico
US$ 574.00 *
Print + Online
Individual Subscription Online only
Euro [D] 460.00
RRP for USA, Canada, Mexico
US$ 689.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Drug Metabolism and Drug Interactions

Editor-in-Chief: Siest, Gérard

Editorial Board Member: Chen, Bing / Devinsky, Ferdinand / Henney, Adriano / Hirata, Rosario D. C. / Ingelman-Sundberg, Magnus / Llerena, Adrián / Manolopoulos, Vangelis G. / Meyer, Urs A. / Patrinos, George / Schaik, Ron / Sadee, Wolfgang / Turpeinen, Miia / Maitland-van de Zee, Anke-Hilse / Zanger, Ulrich M. / Marc, Janja / Hubacek, Jaroslav A.

4 Issues per year

  • High quality manuscript processing through ScholarOne
    Manuscripts®. Please submit your manuscript online at http://mc.manuscriptcentral.com/dmdi
  • Rapid publication times: max. 2 weeks from acceptance to online publication
  • Free publication of color figures both in online and print editions; no page charges
  • Open Access publication option available

    • Aims and Scope

    Drug Metabolism and Drug Interactions (DMDI ) provides up-to-date Research Articles, Reviews and Opinion Papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Areas covered include: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, and neuropsychopharmacology. DMDI also features Short Communications, Letters to the Editor, Case Reports, and Editorials. DMDI is the official journal of the European Society of Pharmacogenomics and Theranostics.

    Submission of Manuscripts

    The editors of Drug Metabolism and Drug Interactions (DMDI) would like to invite submissions for this Journal that has been published at DE GRUYTER since 2010.

    DMDI is devoted to keeping a record of review articles, and state-of-the-art research and to promoting study, research and improvement in, but not limited to, the following fields:

    - Drug Metabolizing Enzymes
    - Pharmacogenetics and Pharmacogenomics
    - Biochemical Pharmacology
    - Molecular Pathology
    - Clinical Pharmacology
    - Pharmacokinetics and Drug Interactions
    - Immunopharmacology
    - Neuropsychopharmacology

    DMDI is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. Since 2010 DMDI has undergone major developments and improvements. There are no page charges, and color figures are published print and online free of charge. Accepted papers will be published online first as DOI-citable, forward-linked articles for quickest possible visibility for the scientific community. The De Gruyter online platform (http://www.degruyter.com/view/j/dmdi) offers a variety of additional author services.

    All manuscripts will be subjected to peer review and their publication will depend on the reviewers’ reports. The online manuscript submission system ScholarOne Manuscripts (http://mc.manuscriptcentral.com/dmdi) guarantees facilitated paper submission and rapid peer review.

    We would be very honored if you would consider DMDI for submission of your work and accept this invitation.

    If you are able to accept we would appreciate giving us a tentative submission deadline when we might expect your article. Please feel free to contact the Editorial Office with any questions you might have at DMDI.editorial@degruyter.com or the Editor in Chief, Prof. Gérard Siest at gerard.siest@pharma.uhp-nancy.fr

    Public Repositories

    Author wishes to include own article in an institutional repository or place own article on a departmental/personal website

    The author's institute can offer access to the authors' final, accepted manuscript version of an article from its repository website. Likewise, authors are allowed to post their final, accepted manuscript version on their own personal or laboratory website. In both cases an embargo period of 12 months after online publication in the journal applies. Unless expressly permitted, authors may not post the publisher's version on their own website. However, it is possible to place a link to the published article PDF for purchase.

    This permission is restricted to non-commercial institutions only; for the conditions regarding article placement on corporate websites, please contact dmdi.editorial@degruyter.com.


    Inclusion of articles in a general repository

    General repositories may include the abstract of the article in the repository and place a link to the publisher's version of the article for purchase.

    NIH-funded authors: WdG acknowledges that the author of an NIH-funded article retains the right to provide a copy of the final, accepted manuscript document to NIH for archiving in PubMed Central 12 months after online publication in the journal. Note that only the accepted author's version of the manuscript, not the PDF file of the published article, may be used for NIH archiving.


    Institutional repository wishes to include articles which do not exist in electronic format

    WdG allows institutional repositories to include a scanned version of their authors' journal articles as published in printed form. We request a link be placed to the journal's homepage (http://www.degruyter.com/view/j/dmdi).


    Author wishes to place a link to the abstract of an article

    Authors may place as many links to the abstract as desired.


    Author wishes to send electronic offprints (PDFs) to colleagues

    Authors will receive an offprint of the publisher's article version as PDF-document. Authors may send up to 30 copies of the PDF document as electronic offprint to colleagues. Any other form of distribution of the electronic offprint file requires written permission from the publisher.

    Drug Metabolism and Drug Interactions is covered by the following abstracting and indexing services:

    • Chemical Abstracts
    • Elsevier: Biobase, EMBASE, Scopus
    • ISI: Biological Abstracts, BIOSIS Previews, International Pharmaceutical Abstracts, Prous Science Integrity
    • Medline
    • ProQuest: Natural Sciences

     

     

    Editor-in-Chief

    Gérard Siest, Nancy, France


    Editorial Board

    Bing Chen, Shanghai, China
    Ferdinand Devinsky, Bratislava, Slovakia
    Adriano Henney, Macclesfield, UK
    Rosario D.C. Hirata, Sao Paulo, Brazil
    Jaroslav A. Hubacek, Prague, Czech Republic
    Magnus Ingelman-Sundberg, Stockholm, Sweden
    Adrián LLerena, Badajoz, Spain
    Anke Hilse Maitland van der Zee, Utrecht, The Netherlands
    Janja Marc, Ljubljana, Slovenia
    Vangelis G. Manolopoulos, Alexandroupolis, Greece
    Urs A. Meyer, Basel, Switzerland
    George P. Patrinos, Patras, Greece
    Wolfgang Sadee, Columbus, OH, USA
    Miia Turpeinen, Oulu, Finland
    Ron H.N. van Schaik, Rotterdam, The Netherlands
    Ulrich M. Zanger, Stuttgart, Germany 

    Editorial Office

    Heike Jahnke, Journal Manager
    Walter de Gruyter GmbH & Co. KG
    Genthiner Str. 13
    10785 Berlin
    Germany
    Tel. +49-30-26005-220
    Fax: +49-30-26005-325
    E-mail: dmdi.editorial@degruyter.com

    Please log in or register to comment.